Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects - Simon, T; Bhatt, D L; Bergougnan, L; Farenc, C; Pearson, K; Perrin, L; Vicaut, E; Lacreta, F; Hurbin, F; Dubar, M (Clinical pharmacology and therapeutics, 2011)
Keywords: Adenosine Diphosphate - pharmacology; Adult; Aryl Hydrocarbon Hydroxylases - genetics; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - pharmacokinetics; Platelet Aggregation Inhibitors - pharmacology; Polymorphism, Genetic; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Ticlopidine - pharmacology; Young Adult